Navigation Links
JPM-TMT Awards New Contract to Study Administration using Marburg Virus Drug

FORT BELVOIR, Va., Sept. 6, 2012 /PRNewswire-USNewswire/ -- A contract to evaluate an alternative method for delivering a medical countermeasure (MCM) was awarded to Sarepta Therapeutics by the Joint Project Manager Transformational Medical Technologies (JPM-TMT).  A component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), JPM-TMT has made significant progress in the development of a therapeutic to fight the highly lethal Marburg virus.  During the course of developing the drug candidate thus far, the intravenous (IV) method of delivery is being utilized.  This new $3.9 million contract will evaluate the feasibility of an intramuscular (IM) route, a more practical administration of a drug.


John Anderson, Product Manager of JPM-TMT's Hemorrhagic Fever Virus-Therapeutics Medical Countermeasures acquisition program, commented on the development of the drug candidate. "With AVI-7288 showing survival rates up to four days post infection, we are eager to determine whether it is feasible to deliver a drug intramuscularly—a route that could reduce the logistical burden of administering the medical countermeasure to our Warfighter. IM delivery is both easier and quicker to administer.  The IV route takes up to one hour while IM administration takes just seconds. The potential for efficient treatment in a mass casualty situation is obvious."

There is no treatment for infection caused by Marburg virus, a member of the Filoviridae family of Hemorrhagic Fever Viruses (HFV).  The disease is characterized by high fever, chills, nausea, vomiting, chest pain, diarrhea, and in some cases, massive hemorrhaging and organ dysfunction. 

"Developing a treatment for the highly lethal Marburg virus infection is ground-breaking," said David E. Hough, Joint Project Manager for JPM-TMT. "JPM-TMT is the only U.S. government agency testing a post-exposure drug candidate against this dangerous disease. Our goal is to successfully develop a therapeutic for the Marburg virus infection using platform technologies that will ultimately have the capacity to rapidly respond to outbreaks of all HFVs as well as other biological pathogens. Both our Warfighters and the nation stand to benefit from our unique approach."

Joint Project Manager Transformational Medical Technologies (JPM-TMT)

JPM-TMT is a component of the U.S. Department of Defense's Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD). JPM-TMT aims to protect the Warfighter from emerging infectious diseases, genetically altered, and unknown biological threats. Through strategic investments and partnerships with innovative biotech firms, pharmaceutical corporations, other government agencies, and academic institutions, JPM-TMT facilitates the advanced development and acquisition of adaptable platform technologies, broad-spectrum medical countermeasures, and innovative systems to enhance our nation's biodefense response capability. For more information, visit

SOURCE Joint Project Manager Transformational Medical Technologies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NSF awards $450,000 to UNH, Conductive Compounds Inc. for solar panel innovation
2. Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting
3. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
4. The Masonry Heater Association of North America Announces the 2012 Masonry Heater, Bake Oven and Masonry Project Awards
5. picoSpin-45 Benchtop NMR Spectrometer a Finalist in the European Life Sciences Awards
6. San Diego Medical Director Wins Two Book Awards For Latest Medical Thriller
7. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
8. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
9. The Scientist Magazine’s 2012 Multimedia Awards—Call for Entries
10. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
11. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
Post Your Comments:
(Date:12/1/2015)... 2015 ) ... U.K. Virology and Bacteriology Testing Market: Sales ... Supplier Shares by Test, Innovative Technologies, Competitive ... --> ) has announced ... and Bacteriology Testing Market: Sales and Volume ...
(Date:11/30/2015)... , Dec. 1, 2015  An interventional radiology technique ... to the preliminary results of a study being presented today ... North America (RSNA). ... done for decades by interventional radiologists as a way to ... the procedure as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... JACKSONVILLE, Florida , November 30, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, today announced it will be presenting ... Event on December 1, 2015 at 2.30 PM PT. ... member and Strategic Advisor will be giving the presentation ...
Breaking Biology Technology:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
Breaking Biology News(10 mins):